<DOC>
	<DOC>NCT03019614</DOC>
	<brief_summary>This was an open label, randomized, single dose, three period crossover pharmacokinetic study of Chronocort® in 30 healthy male volunteers. The study was conducted in smaller sub groups (Group 1, n=18 and Group 2, n=12).</brief_summary>
	<brief_title>An Open Label Study in Healthy Volunteers to Compare Chronocort® to Hydrocortisone</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Adrenal Hyperplasia, Congenital</mesh_term>
	<mesh_term>Adrenogenital Syndrome</mesh_term>
	<mesh_term>Adrenal Insufficiency</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<criteria>Healthy male volunteers between 18 and 60 years of age, inclusive (at screening). Subjects with a Body Mass Index (BMI) of 2128. Body Mass Index = Body weight (kg) / (Height (m))2. Subjects with no clinically significant abnormal serum biochemistry, haematology and urine examination values within 14 days of the start of the study. The parameters measured included those shown in Appendix 3 of the Study Protocol. Subjects with a negative urinary drugs of abuse screen (including alcohol), determined within 14 days of the start of the study. Subjects with negative HIV and Hepatitis B and C results. Subjects with no clinically significant abnormalities in 12lead electrocardiogram (ECG) determined within 14 days of the start of the study. Subjects with no clinicallysignificant deviation outside the normal ranges for blood pressure and pulse measurements. Subjects and sexual partners must have used effective contraception methods during the trial and for 3 months after the last dose, for example: Oral contraceptive + condom Intrauterine device (IUD) + condom Diaphragm with spermacide + condom Subjects must have been available to complete the study. Subjects must have satisfied a medical examiner about their fitness to participate in the study. Subjects must have provided written informed consent to participate in the study. A clinically significant history of gastrointestinal disorder likely to influence drug absorption. Receipt of regular medication within 14 days of the first study day (including high dose vitamins, dietary supplements or herbal remedies). Evidence of renal, hepatic, central nervous system, respiratory, cardiovascular or metabolic dysfunction. A clinically significant history of previous allergy / sensitivity to Hydrocortisone. A clinically significant history of drug or alcohol abuse. Inability to communicate well with the Investigator (i.e., language problem, poor mental development or impaired cerebral function). Participation in a New Chemical Entity clinical study within the previous 16 weeks or a marketed drug clinical study within the previous 12 weeks. Subjects who had consumed more than 2 units of alcohol per day within seven (7) days prior to the first dose or had consumed any alcohol within the 48 hour period prior to the first dose. Donation of 450ml or more blood within the previous 12 weeks. Subjects who worked shifts (i.e. regularly alternated between days, afternoons and nights).</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>